Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,228 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07708987 | Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.(Withaferin_A) | recruiting | Phase 2 | 34 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 |
| clinicaltrials |
| NCT07709013 | Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients | recruiting | Phase 2 | 22 | Tata Memorial CentreOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00501826 | Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 160 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01371630 | Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 276 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients(STOMP) | recruiting | Phase 1 / Phase 2 | 300 | Karyopharm Therapeutics IncINDUSTRY | 2 | Jul 15, 2026 | clinicaltrials |
| NCT02494700 | Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT05464719 | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07128381 | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | recruiting | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | not yet recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01096602 | Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission | completed | Phase 2 | 63 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05038592 | Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes | active not recruiting | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05351593 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | recruiting | Phase 1 / Phase 2 | 35 | James RubensteinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05847569 | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | recruiting | Phase 2 | 62 | Mayo ClinicOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis(NEXICART-2) | active not recruiting | Phase 1 / Phase 2 | 45 | Nexcella Inc.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 2 | 60 | Hematology department of the 920th hospitalOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | terminated | Phase 2 | 135 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04792489 | DALY II USA/ MB-CART2019.1 for DLBCL | recruiting | Phase 2 | 315 | Miltenyi Biomedicine GmbHINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT04822337 | Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05199311 | Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma | suspended | Phase 1 / Phase 2 | 66 | Hackensack Meridian HealthOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06164275 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06523621 | Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | active not recruiting | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06698822 | A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07228273 | Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia | recruiting | Phase 2 | 102 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07302347 | A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) | recruiting | Phase 1 / Phase 2 | 20 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03399773 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | active not recruiting | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04419519 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | active not recruiting | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05303792 | Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 68 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05442216 | Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents(TAGALONG) | recruiting | Phase 2 | 53 | Joshua ZeidnerOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | active not recruiting | Phase 1 / Phase 2 | 53 | Columbia UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06558604 | Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma(GLOASIS) | recruiting | Phase 2 | 100 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 40 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma(ELARA) | completed | Phase 2 | 98 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 9, 2026 | clinicaltrials |
| NCT04439201 | Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | active not recruiting | Phase 2 | 1 | University of UtahOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06637501 | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 94 | BeOne MedicinesINDUSTRY | 6 | Jul 9, 2026 | clinicaltrials |
| NCT01880567 | Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03269669 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06140524 | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma(LINKER-MGUS1) | recruiting | Phase 2 | 116 | Regeneron PharmaceuticalsINDUSTRY | 7 | Jul 8, 2026 | clinicaltrials |
| NCT06723457 | Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | recruiting | Phase 2 | 34 | Reem KarmaliOTHER | 1 | Jul 8, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 16, 2026source: clinicaltrials